Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgolide B is a diterpene lactone and the most potent member of the ginkgolide family, isolated from the leaves of the Ginkgo biloba tree. It is a major active component of standardized Ginkgo biloba extracts (notably EGb 761). Ginkgolide B acts primarily as a potent antagonist of platelet-activating factor (PAF) by binding to and inhibiting the PAF receptor, which underlies its anti-inflammatory, anti-allergic, antioxidant, neuroprotective, and anti-coagulant effects. Additional mechanisms include inhibition of TLR4-mediated inflammatory responses, scavenging free radicals via NF-kB inhibition, modulation of glutamatergic transmission in the central nervous system, reduction in Ca2+-stimulated intracellular events, and promotion of endothelial progenitor cell proliferation through vascular endothelial growth factor (VEGF) pathways. It has been studied for use in migraine prophylaxis as a nutraceutical approach and may have potential anticancer effects by inducing apoptosis or inhibiting oxidative stress generation[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgolide b.